These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The underlying mechanisms for development of hypertension in the metabolic syndrome. Yanai H; Tomono Y; Ito K; Furutani N; Yoshida H; Tada N Nutr J; 2008 Apr; 7():10. PubMed ID: 18416854 [TBL] [Abstract][Full Text] [Related]
28. Biomedicine. A sympathetic defense against obesity. Dulloo AG Science; 2002 Aug; 297(5582):780-1. PubMed ID: 12161638 [No Abstract] [Full Text] [Related]
29. The sympathetic nervous system and obesity: role in aetiology and treatment. Snitker S; Macdonald I; Ravussin E; Astrup A Obes Rev; 2000 May; 1(1):5-15. PubMed ID: 12119646 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risk of adipokines: a review. Dutheil F; Gordon BA; Naughton G; Crendal E; Courteix D; Chaplais E; Thivel D; Lac G; Benson AC J Int Med Res; 2018 Jun; 46(6):2082-2095. PubMed ID: 28974138 [TBL] [Abstract][Full Text] [Related]
31. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. da Silva AA; do Carmo JM; Li X; Wang Z; Mouton AJ; Hall JE Can J Cardiol; 2020 May; 36(5):671-682. PubMed ID: 32389340 [TBL] [Abstract][Full Text] [Related]
34. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Grassi G Hypertens Res; 2006 Nov; 29(11):839-47. PubMed ID: 17345783 [TBL] [Abstract][Full Text] [Related]
35. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. Esler M; Kaye D J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S1-7. PubMed ID: 11346214 [TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Karapanagiotidis S; Wong C; Richards K; Marusic P; Dixon JB; Schlaich MP; Lambert EA J Clin Endocrinol Metab; 2014 Sep; 99(9):E1701-7. PubMed ID: 24937541 [TBL] [Abstract][Full Text] [Related]
37. Pathophysiology of essential hypertension: an update. Saxena T; Ali AO; Saxena M Expert Rev Cardiovasc Ther; 2018 Dec; 16(12):879-887. PubMed ID: 30354851 [TBL] [Abstract][Full Text] [Related]
38. High blood pressure management: potential benefits of I1 agents. Esler M J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906 [TBL] [Abstract][Full Text] [Related]
39. Sex differences in sympathetic activity in obesity and its related hypertension. Fu Q Ann N Y Acad Sci; 2019 Oct; 1454(1):31-41. PubMed ID: 31087350 [TBL] [Abstract][Full Text] [Related]
40. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. Frigolet ME; Torres N; Tovar AR J Nutr Biochem; 2013 Dec; 24(12):2003-15. PubMed ID: 24120291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]